Search

Your search keyword '"Fernandez-Carballido C"' showing total 27 results
Start Over Author "Fernandez-Carballido C" Publication Year Range Last 50 years
27 results on '"Fernandez-Carballido C"'

1. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY

Author

Prieto-Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela-Casasempere P, Narvaez J, Aldasoro V, Maiz O, Fernandez-Lopez C, Gonzalez M, Melero R, Villa-Blanco I, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Sanchez-Martin J, Fernandez E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Galindez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gomez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Gonzalez J, De Dios J, Andreu J, de Pedro I, Revenga M, Valdivieso J, Rosa R, De la Morena I, Fernandez-Llanio N, Labrador E, Roman-Ivorra J, Ortiz-Sanjuan F, Garcia-Valle A, Gallego A, Iniguez C, Garrido-Punal N, De la Torre R, Lopez-Gonzalez R, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Feijoo M, Fernandez C, Rua-Figueroa I, Conesa A, Arija S, Gonzalez-Gay M, and Blanco R

Published
2022

3. CARDIOVASCULAR AND DISEASE RELATED FEATURES IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT PSORIASIS. A MULTICENTER STUDY WITH 882 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Vicente-Rabaneda E, Fernandez-Carballido C, Martinez-Vidal M, Anino-Fernandez D, Plasencia D, Vivar M, Galindez E, Perez E, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

4. Psoriatic arthritis screening: A systematic literature review and experts' recommendations

Author

Urruticoechea-Arana A, Benavent D, Leon F, Almodovar R, Belinchon I, de la Cueva P, Fernandez-Carballido C, Loza E, Gratacos J, and Cribado Working Grp

Abstract

Objective To analyze the performance of psoriatic arthritis (PsA) screening tools, examine their implementation in daily practice, and reach a consensus about the best screening tool for implementation in daily practice in different medical settings. Methods A systematic literature review (SLR), structured telephone interviews to hospitals, and a multidisciplinary nominal group meeting were all conducted. The SLR employed sensitive search strategies using Medline, Embase, and the Cochrane Library up to January 2020. Two reviewers independently selected articles that reported data on PsA screening tools and that included sufficient data to at least calculate the sensitivity and specificity of those tools (e.g., questionnaires, algorithms, specific questions, and biomarkers). The hospital interviews collected data regarding the process of suspected PsA diagnosis and referral to rheumatology, the implementation of PsA screening tools, and barriers and facilitators to implementation of those tools. In the nominal group meeting, a multidisciplinary team of experts discussed all these data and subsequently recommended a screening tool for implementation. Results The SLR included 41 moderate-quality studies that analyzed 14 PsA screening tools, most of which were questionnaire-based tools. All of these studies reported a moderate-good performance but presented different characteristics regarding the time to completion or the number and type of items or questions. The implementation of screening tools was low (30.5%). The experts ultimately recommended regular use of a PsA screening tool, preferably the PURE-4 questionnaire. Conclusions The implementation of PsA screening tools like the PURE-4 questionnaire in daily practice likely improves the prognosis of PsA patients.

Published
2021

6. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

Author

Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Subjects
Takayasu's arteritis, cDMARDs, biological therapy, Caucasian, Tocilizumab
Abstract

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

Published
2021

7. ROLE OF VASPIN IN ATHEROSCLEROTIC DISEASE AND CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS

Author

Rueda-Gotor J, Lopez-Mejias R, Remuzgo-Martinez S, Cueto V, Corrales A, Lera-Gomez L, Portilla V, Gonzalez-Mazon I, Blanco R, Exposito R, Mata C, Llorca J, Hernandez-Hernandez V, Rodriguez-Lozano C, Puerto N, Castro R, Castaneda N, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Plasencia C, Galindez E, Vivar M, Gualillo O, Quevedo-Abeledo J, Castaneda S, Ferraz-Amaro I, Gonzalez-Gay M, and Genre F

Published
2021

8. TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS

Author

Prieto-Pena D, Bernabeu P, Vela-Casasempere P, Narvaez J, Fernandez-Lopez C, Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Ortego N, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Arija S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Sanjuan F, de Pedro I, Valdivieso J, Laura P, Rosa R, Fernandez-Llanio N, de la Torre R, Suarez S, Montesa M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Published
2021

9. COMPARISON OF CAROTID SUBCLINICAL ATHEROSCLEROSIS AND STRUCTURAL DAMAGE IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY WITH 886 PATIENTS.. A MULTICENTER STUDY WITH 886 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Garcia-Castaneda N, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Plasencia C, Vivar M, Galindez E, Perez E, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

10. COMPARISON OF CAROTID SUBCLINICAL ATHEROSCLEROSIS AND STRUCTURAL DAMAGE IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT ANTERIOR UVEITIS. A MULTICENTER STUDY WITH 886 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Vicente-Rabaneda E, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Vivar M, Galindez E, Perez E, Demetrio-Pablo R, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

19. GENETIC AND FUNCTIONAL STUDY OF OMENTIN REGARDING CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS

Author

Genre F, Rueda-Gotor J, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Mijares V, Lera-Gomez L, Portilla V, Exposito R, Mata C, Ferraz-Amaro I, Hernandez-Hernandez V, Castaneda S, Vicente E, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Quevedo-Abeledo J, Rodriguez-Lozano C, Blanco R, Gualillo O, Ibanez J, Llorca J, Lopez-Mejias R, and Gonzalez-Gay M

Published
2019

20. Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients

Author

Genre F, Rueda-Gotor J, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Mijares V, Lera-Gomez L, Portilla V, Exposito R, Mata C, Ferraz-Amaro I, Hernandez-Hernandez V, Castaneda S, Vicente-Rabaneda E, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Quevedo-Abeledo J, Rodriguez-Lozano C, Blanco R, Garcia-Vivar M, Galindez-Agirregoikoa E, Llorca J, Lopez-Mejias R, and Gonzalez-Gay M

Published
2019

21. Hyperlipoprotein(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

Author

García-Gómez MC, Martín-Martínez MA, Fernandez-Carballido C, Castañeda S, González-Juanatey C, Sanchez-Alonso F, González-Fernández MJ, Sanmartí R, García-Vadillo JA, Fernández-Gutiérrez B, García-Arias M, Manero FJ, Senabre J, Rueda-Cid A, Ros-Expósito S, Pina-Salvador JM, Erra-Durán A, Möller-Parera I, Llorca J, González-Gay MA, and CARMA Project Collaborative Group

Subjects
musculoskeletal diseases, stomatognathic diseases
Abstract

Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors.

Published
2019

26. Bosentan therapy for cutaneous fibrosis in systemic sclerosis

Author

Alegre-Sancho, J. J., primary, Roman-Ivorra, J. A., additional, Chalmeta-Verdejo, C., additional, Fernandez-Carballido, C., additional, Fernández-Llanio, N., additional, Ivorra-Cortes, J., additional, Hortal-Alonso, R., additional, Alcañiz-Escandell, C., additional, Abad-Franch, L., additional, Valls-Pascual, E., additional, Senabre-Gallego, J. M., additional, and Muñoz-Gil, S., additional

Published
2007
Full Text
View/download PDF

27. [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis].

Author

Juanola Roura X, Zarco Montejo P, Sanz Sanz J, Muñoz Fernández S, Mulero Mendoza J, Linares Ferrando LF, Gratacós Masmitja J, García de Vicuña R, Fernandez Carballido C, Collantes Estevez E, Batlle Gualda E, Ariza Ariza R, and Loza Santamaría E

Subjects
Adalimumab, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents administration & dosage, Antirheumatic Agents therapeutic use, Biological Therapy methods, Drug Therapy, Combination, Etanercept, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G adverse effects, Immunoglobulin G therapeutic use, Infliximab, Methotrexate administration & dosage, Methotrexate therapeutic use, Receptors, Tumor Necrosis Factor administration & dosage, Receptors, Tumor Necrosis Factor therapeutic use, Spondylarthritis classification, Sulfasalazine administration & dosage, Sulfasalazine therapeutic use, Biological Therapy standards, Spondylarthritis drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Objective: Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT., Methods: Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique., Results: We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching., Conclusions: We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA., (Copyright © 2010 Elsevier España, S.L. All rights reserved.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results